Published Date: 01 Mar 2023
Benign prostatic hyperplasia (BPH) is a condition in which the prostate gland enlarges, causing problems or obstruction in urination...
Read Full NewsA new phase 2 study presented at AES 2025 showed that stiripentol may reduce seizure burden in patients with Lennox-Gastaut syndrome.
Sharon Hesterlee, PhD, President and CEO of the Muscular Dystrophy Association, discussed the 2026 MDA Conference, the significance of its keynote speaker, and the evolving therapeutic landscape in neuromuscular medicine.
A new study presented at AES 2025 examined factors linked to declining surgery for pediatric drug-resistant epilepsy and highlighted variability in candidate selection across centers.
The positive interim findings research represents the first clinical data for ETX101, an investigational cell-type-selective gene therapy, and the first potential one-time disease-modifying treatment for Dravet syndrome.
Lingdolinurad Demonstrates Dose-Dependent Serum Uric Acid Reductions
House Dust Mite SLIT Tablet Well Tolerated in Children With Allergic Asthma
AI in Dermatology: Discussing Downsides to the Adoption of Artificial Intelligence
1.
Even after a partial ban, asbestos is still used and is a deadly carcinogen, according to the EPA.
2.
For relapsed or resistant DLBCL, odronextamab produced positive results.
3.
Medical Journal March 28, 2023
4.
recognizing the mechanism by which the replication of the host cell is outperformed by the skin cancer virus.
5.
Study finds 81% of cancer cures touted by TikTok videos are fake
1.
Neoadjuvant Radiotherapy & Endocrine Therapy in ER+ Breast Cancer Treatment
2.
Unleashing the Oncolytic Arsenal: Talimogene Laherparepvec Monotherapy – A Targeted Cancer Immunotherapy Treatment
3.
Unlocking the Potential of Onivyde: A New Hope for Cancer Treatment
4.
The Truth About Marijuana and Its Effect on Mental Health
5.
The Role of Calcium Corrections in Accurate Blood Test Results
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Efficient Management of First line ALK-rearranged NSCLC - Part VI
2.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
3.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part III
4.
An Intro to The Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer Clinical Studies.
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation